Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06745076 · ClinicalTrials.gov registry record · Phase 2

Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma

A Phase 2 study of Classic Hodgkin Lymphoma and Advanced Hodgkin Lymphoma, sponsored by University of Washington.

Recruiting
Registry status
Phase 2
Development phase
125
Enrollment target
5
Study locations

NCT06745076: Recruiting Phase 2 study of Classic Hodgkin Lymphoma and Advanced Hodgkin Lymphoma, sponsored by University of Washington.

NCT06745076 is a Phase 2 study of Classic Hodgkin Lymphoma and Advanced Hodgkin Lymphoma that is actively recruiting participants, run by University of Washington. The registered enrollment target is 125 participants, below the 239-participant average among 9 other Classic Hodgkin Lymphoma trials with a reported enrollment target (48% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06745076, a Phase 2 study of Classic Hodgkin Lymphoma and Advanced Hodgkin Lymphoma, is actively recruiting participants, sponsored by University of Washington.

RECRUITING
Registry status
Phase 2
Development phase
125 participants
Enrollment target
5
Study locations

Study Summary

This phase II trial tests how well personalized reduction of chemotherapy (nivolumab, doxorubicin, vinblastine and dacarbazine) based on circulating tumor deoxyribonucleic acid (ctDNA) evaluation works for treating patients with Hodgkin lymphoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Chemotherapy drugs, such as nivolumab, doxorubicin, vinblastine and dacarbazine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Many types of tumors tend to lose cells or release different types of cellular products including their DNA, which is referred to as ctDNA, into the bloodstream before changes can be seen on scans. Health care providers can measure the level of ctDNA in blood or other bodily fluids and, based on the result, assign patients to a reduced number of chemotherapy treatments or the standard number of chemotherapy treatments. Using ctDNA to assign a personalized reduction of chemotherapy may be effective in treating patients with advanced Hodgkin lymphoma.

Conditions Studied

Classic Hodgkin Lymphoma Advanced Hodgkin Lymphoma Lugano Classification Stage III Hodgkin Lymphoma AJCC v8 Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Computed Tomography
  • DRUG Doxorubicin
  • PROCEDURE Echocardiography Test
  • DRUG Dacarbazine

Study Locations (5)

California

  • City of Hope - Irvine

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Missouri

  • Washington University in St. Louis - St Louis

New York

  • Memorial Sloan Kettering Cancer Center - New York

Washington

  • Fred Hutch/University of Washington Cancer Consortium - Seattle

Trial Details

FieldValue
Enrollment Target 125 participants
Start Date 2025-03-06
Est. Completion 2033-01-03
Phase Phase 2
University of Washington

1,048 total trials

What NCT06745076 shows while recruiting

NCT06745076 is an interventional study that assigns participants to a tested intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, below the 239-participant average among 9 other Classic Hodgkin Lymphoma trials with a reported enrollment target (48% lower).

The record links to 4 conditions, with Classic Hodgkin Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT06745076 lists 5 locations in 5 states (California, Massachusetts, Missouri).

Frequently Asked Questions

What is clinical trial NCT06745076 about?

NCT06745076 is a clinical study titled "Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma". This phase II trial tests how well personalized reduction of chemotherapy (nivolumab, doxorubicin, vinblastine and dacarbazine) based on circulating tumor deoxyribonucleic acid (ctDNA) evaluation works for treating patients with Hodgkin lymphoma that may have spread from where it first started to ne...

What is the current status of trial NCT06745076?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 125 participants. The study started on 2025-03-06. Estimated completion is 2033-01-03.

What conditions does trial NCT06745076 study?

This clinical trial studies the following conditions: Classic Hodgkin Lymphoma, Advanced Hodgkin Lymphoma, Lugano Classification Stage III Hodgkin Lymphoma AJCC v8, Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8.

What interventions are being tested in trial NCT06745076?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Doxorubicin (DRUG), Echocardiography Test (PROCEDURE), Dacarbazine (DRUG).

Who is sponsoring clinical trial NCT06745076?

This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06745076 being conducted?

This trial has 5 study locations across California, Massachusetts, Missouri, New York, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Classic Hodgkin Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06745076's enrollment target sits among peer trials

125 5th of 9 higher than 5 of 9 other Classic Hodgkin Lymphoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Classic Hodgkin Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02717039 · 125 participants

    Pharmacogenomics of Heparin-Induced Thrombocytopenia

  • NCT02763033 · 125 participants · Phase 2

    Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients

  • NCT02793999 · 125 participants

    Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia

  • NCT03003299 · 125 participants · NA

    PARTNER 3 Trial - Aortic Valve-in-Valve

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06745076

Source: ClinicalTrials.gov NCT06745076, the US trial registry maintained by the National Library of Medicine. NCT06745076 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.